全球寡核苷酸CDMO市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球寡核苷酸CDMO市場預計將從2025年的34.5億美元成長至2034年的206億美元，預計在2026年至2034年間以21.96%的複合年成長率成長。該市場正經歷快速成長，主要原因是製藥和生物技術公司擴大將基於寡核苷酸的療法的開發和生產外包。合約開發和生產組織（CDMO）透過提供專業知識、先進的生產能力和監管支持，正在加速藥物研發進程。對精準醫療、基因療法和核酸療法的投資不斷增加，也顯著推動了市場擴張。製造技術的持續進步正在提高產品品質和擴充性。

對RNA療法、反義寡核苷酸和基因靜默技術日益成長的需求是推動產業成長的主要動力。製藥公司正與專業的合約研發生產機構（CDMO）合作，以利用其高品質的生產基礎設施、降低營運成本並加快產品上市速度。活性化的研發活動、不斷擴展的臨床管線以及有利的監管趨勢，都創造了強勁的商業機會。合成、純化和品管的技術進步，持續提升生產能力。

隨著基因療法和個人化醫療的不斷發展，前景依然十分光明。對生物技術研究、先進生產設施和創新治療平台的投資不斷增加，將持續推動對合約研發生產（CDMO）服務的需求。人工智慧、自動化和數位化製造技術有望提高生產效率和合規性。持續的創新和策略合作將支撐全球寡核苷酸CDMO市場的整體長期成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球寡核苷酸CDMO市場：依服務類型分類

• 市場分析、洞察與預測
• 契約製造（臨床階段、商業化階段）
• 合約開發
• 分析和品管服務
• 監管和CMC支援服務

第5章：全球寡核苷酸CDMO市場：以寡核苷酸類型分類

• 市場分析、洞察與預測
• 反義寡核苷酸
• 小干擾RNA
• 引導RNA
• 適體
• 其他類型的寡核苷酸

第6章 全球寡核苷酸CDMO市場：依應用分類

• 市場分析、洞察與預測
• 治療應用（罕見疾病、腫瘤、神經病變、心血管代謝疾病、感染疾病）
• 出於研究目的
• 診斷用途
• 其他

第7章 全球寡核苷酸CDMO市場：依最終用戶分類

• 市場分析、洞察與預測
• 製藥和生物技術公司
• 診斷相關企業
• 學術研究機構
• 基因療法和細胞療法開發公司
• 其他最終用戶

第8章 全球寡核苷酸CDMO市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Agilent Technologies Inc
  • Ajinomoto Co. Inc
  • Almac Group Limited
  • Asymchem Laboratories（Tianjin）Co. Ltd
  • Bachem Holding AG
  • BioSpring GmbH
  • CordenPharma International
  • Curia Global Inc
  • EUROAPI SA
  • Eurofins Scientific SE
  • GenScript Biotech Corporation
  • Kaneka Corporation
  • Lonza Group Ltd
  • Maravai LifeSciences Holdings Inc
  • Merck KGaA
  • PolyPeptide Group AG
  • ST Pharm Co. Ltd
  • Syngene International Limited
  • Thermo Fisher Scientific Inc
  • WuXi AppTec Co. Ltd

The global oligonucleotide CDMO market size is expected to reach USD 20.60 Billion in 2034 from USD 3.45 Billion in 2025, growing at a CAGR of 21.96 during 2026-2034.This market is experiencing rapid growth as pharmaceutical and biotechnology companies increasingly outsource the development and manufacturing of oligonucleotide-based therapeutics. Contract development and manufacturing organizations provide specialized expertise, advanced production capabilities, and regulatory support that accelerate drug development timelines. Rising investments in precision medicine, genetic therapies, and nucleic acid-based treatments are significantly driving market expansion. Continuous advancements in manufacturing technologies are improving production quality and scalability.

Growing demand for RNA therapeutics, antisense oligonucleotides, and gene-silencing technologies is a major factor supporting industry growth. Pharmaceutical companies are partnering with specialized CDMOs to access high-quality manufacturing infrastructure while reducing operational costs and accelerating commercialization. Increasing research activities, expanding clinical pipelines, and favorable regulatory developments are creating strong business opportunities. Technological improvements in synthesis, purification, and quality control continue strengthening manufacturing capabilities.

Future prospects remain exceptionally promising as genetic medicine and personalized therapeutics continue advancing. Expanding investments in biotechnology research, advanced manufacturing facilities, and innovative therapeutic platforms will generate sustained demand for CDMO services. Artificial intelligence, automation, and digital manufacturing technologies are expected to improve production efficiency and regulatory compliance. Continued innovation and strategic collaborations will support long-term growth across the global oligonucleotide CDMO market.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Service Type

• Contract Manufacturing (Clinical Stage, Commercial Stage)
• Contract Development
• Analytical and Quality Control Services
• Regulatory and CMC Support Services

By Oligonucleotide Type

• Antisense Oligonucleotides
• Small Interfering RNA
• Guide RNA
• Aptamers
• Other Oligonucleotide Types

By Application

• Therapeutic Applications (Rare Diseases, Oncology, Neurology, Cardiometabolic Diseases, Infectious Diseases)
• Research Applications
• Diagnostic Applications
• Others

By End User

• Pharmaceutical & Biotechnology Companies
• Diagnostic Companies
• Academic & Research Institutes
• Gene Therapy & Cell Therapy Developers
• Other End Users

COMPANIES PROFILED

• Agilent Technologies Inc., Ajinomoto Co. Inc., Almac Group Limited, Asymchem Laboratories (Tianjin) Co. Ltd., Bachem Holding AG, BioSpring GmbH, CordenPharma International, Curia Global Inc., EUROAPI S.A., Eurofins Scientific SE, GenScript Biotech Corporation, Kaneka Corporation, Lonza Group Ltd., Maravai LifeSciences Holdings Inc., Merck KGaA, PolyPeptide Group AG, ST Pharm Co. Ltd., Syngene International Limited, Thermo Fisher Scientific Inc., WuXi AppTec Co. Ltd.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL OLIGONUCLEOTIDE CDMO MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Service Type
• 4.2. Contract Manufacturing (Clinical Stage, Commercial Stage) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Contract Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Analytical and Quality Control Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Regulatory and CMC Support Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL OLIGONUCLEOTIDE CDMO MARKET: BY OLIGONUCLEOTIDE TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Oligonucleotide Type
• 5.2. Antisense Oligonucleotides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Small Interfering RNA Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Guide RNA Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Aptamers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Oligonucleotide Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL OLIGONUCLEOTIDE CDMO MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Therapeutic Applications (Rare Diseases, Oncology, Neurology, Cardiometabolic Diseases, Infectious Diseases) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Research Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Diagnostic Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL OLIGONUCLEOTIDE CDMO MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Diagnostic Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Gene Therapy & Cell Therapy Developers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL OLIGONUCLEOTIDE CDMO MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Service Type
  • 8.2.2 By Oligonucleotide Type
  • 8.2.3 By Application
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Service Type
  • 8.3.2 By Oligonucleotide Type
  • 8.3.3 By Application
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Service Type
  • 8.4.2 By Oligonucleotide Type
  • 8.4.3 By Application
  • 8.4.4 By End User
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Service Type
  • 8.5.2 By Oligonucleotide Type
  • 8.5.3 By Application
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Service Type
  • 8.6.2 By Oligonucleotide Type
  • 8.6.3 By Application
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL OLIGONUCLEOTIDE CDMO INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Agilent Technologies Inc
  • 10.2.2 Ajinomoto Co. Inc
  • 10.2.3 Almac Group Limited
  • 10.2.4 Asymchem Laboratories (Tianjin) Co. Ltd
  • 10.2.5 Bachem Holding AG
  • 10.2.6 BioSpring GmbH
  • 10.2.7 CordenPharma International
  • 10.2.8 Curia Global Inc
  • 10.2.9 EUROAPI S.A
  • 10.2.10 Eurofins Scientific SE
  • 10.2.11 GenScript Biotech Corporation
  • 10.2.12 Kaneka Corporation
  • 10.2.13 Lonza Group Ltd
  • 10.2.14 Maravai LifeSciences Holdings Inc
  • 10.2.15 Merck KGaA
  • 10.2.16 PolyPeptide Group AG
  • 10.2.17 ST Pharm Co. Ltd
  • 10.2.18 Syngene International Limited
  • 10.2.19 Thermo Fisher Scientific Inc
  • 10.2.20 WuXi AppTec Co. Ltd